New CEO strengthens management

Porto-based FairJourney Biologics S.A. (FJBio), a global leader in antibody research and development, announced today that Dr Werner Lanthaler has been appointed as Chief Executive Officer (CEO). After nearly 14 years at the helm of the company, founder António Parada will now focus on FJBio’s innovation strategy as a member of the Supervisory Board.

Prior to his surprise resignation in early 2024, Lanthaler served as CEO of Evotec SE (Hamburg) for 15 years and played a key role in establishing the company as a global leader in drug discovery, particularly in precision medicine. Before joining Evotec, he was CFO of Austria’s Intercell AG (part of Valneva since May 2013), where he was responsible for the company’s IPO and the successful market launch of its vaccines.

Newly appointed FJBio CEO stated:“Shared data- and AI-driven innovation platforms will be critical to accelerating drug discovery while reducing development timelines and costs. FairJourney Biologics is best positioned to be the global leader in delivering significant efficiency gains resulting from the entire ‘Gene to Clone’ process for its partners. I am honored to lead FJBio into its next growth phase.”

Founder António Parada, now member of the supervisory board of FairJourney Biologics, believes, that the company is only at the beginning of its mission to become a leader in rapid antibody development. “Innovation will play a central role in delivering transformative benefits to our partners”, he said.